VEGFA and Ewing sarcoma: Anti-angiogenic drugs that target VEGF (vascular endothelial growth factor) or VEGF receptors have shown efficacy in 13 cases of primary retroperitoneal Ewing sarcoma, resulting in tumor shrinkage, no progression in the tumor growth, and, in one case, complete remission [9].